Binbin QIAN¹, Xiaoduo LIU², Xiaolin GU¹, Lu YANG³, Dake CHEN^1,*

BIOCELL, Vol.44, No.1, pp. 19-26, 2020, DOI:10.32604/biocell.2020.07859 - 01 March 2020

Abstract Prolylcarboxypeptidase (PRCP) belongs to the S28 family of proteases, which is also a dipeptidyl peptidase. In this study, we demonstrate the expression pattern of PRCP in Non-small cell lung cancer (NSCLC). We found that the repression of PRCP expression by small interfering RNA successfully inhibited cell proliferation, migration, and invasion. Further, we explored the involvement of PRCP in the regulation of epithelial-mesenchymal transition (EMT). The epithelial marker E-cadherin was significantly increased, meanwhile mesenchymal markers MUC1, vimentin, and SNAIL were markedly decreased in PRCP knockdown cells. Moreover, the downregulation of PRCP in the NSCLC cells induced More >

Hatim Thaker, Saum Ghodoussipour, Mateen Saffarian, Akbar Ashrafi, Gus Miranda, Jie Cai, Anne K. Schuckman, Monish Aron, Mihir Desai, Inderbir S. Gill, Siamak Daneshmand, Hooman Djaladat

Canadian Journal of Urology, Vol.26, No.1, pp. 9654-9659, 2019

Abstract Introduction: To evaluate the reasons leading to an extended hospital stay (EHS) in patients undergoing radical cystectomy (RC) with postoperative enhanced recovery after surgery (ERAS) protocol.
Materials and methods: A total of 509 patients underwent RC and urinary diversion with ERAS between May 2012 and March 2017. The protocol includes no bowel preparation, early feeding, predominantly non-narcotic pain control, and μ opioid antagonists. Non-consenting/lost to follow-up patients, and those with non-urothelial carcinoma were excluded. We defined EHS as ≥ 5 postoperative days and compared the cohort to those with a length of stay (LOS) of ≤ 4… More >

Nirmish Singla¹, Jordon T. Walker¹, Solomon L. Woldu¹, Karen De La Fuente¹, Ellen Araj², Brandon Swartz², Payal Kapur^1,2, Claus G. Roehrborn¹

Canadian Journal of Urology, Vol.26, No.1, pp. 9634-9643, 2019

Abstract Introduction: To determine whether quantifying the proximity of positive prostate biopsy cores to the capsular edge may aid in identifying patients at risk for extracapsular extension (ECE) at the time of radical prostatectomy (RP).
Materials and methods: We reviewed a single-surgeon experience of 429 systematic transrectal prostate biopsies from 2010-2014. Marking ink was applied to the capsular edge ex vivo following specimen acquisition, and the proximity of cancer to the stained capsular edge was measured. Primary outcome was ECE at RP. Demographics, PSA, DRE findings, Gleason score, core location and involvement, and RP pathology were recorded. Predictors… More >

Heide Schatten

Canadian Journal of Urology, Vol.26, No.1, pp. 9627-9627, 2019

Abstract This article has no abstract. More >

Kellan F. Clark¹, Matthew Risendal¹, Sharon Hill², Samuel Deem³

Canadian Journal of Urology, Vol.26, No.2, pp. 9715-9719, 2019

Abstract Introduction: The TNM staging system is used globally as the standard for interpreting the extent of cancer. Currently, T3a renal cell carcinoma is classified as tumor extending into the perinephric fat or renal vein. Prognostic outcomes may vary among renal cell carcinomas with renal vein involvement (RVI) versus those with perinephric fat involvement (PFI).
Materials and methods: We reviewed the medical records of all patients who underwent radical or partial nephrectomy at our institution by a single group of urologists between 2000 and 2014. After identifying those patients with T3a renal cell carcinoma, we further analyzed their… More >

Andrew Salner¹, Ilene Staff², Rene I. Jahiel¹, Keith M. Bellizzi³, Alison Champagne², Joseph Tortora², Alison G. Wong³, Tara McLaughlin⁴, Joseph Wagner⁴

Canadian Journal of Urology, Vol.26, No.2, pp. 9708-9714, 2019

Abstract Introduction: We compared the return-to-work interval (RTWI) after radical retro-pubic prostatectomy (RRP) and robot-assisted laparoscopic prostatectomy (RALP) in men being treated for early-stage prostate cancer.
Materials and methods: We mailed a 28-item questionnaire to a random sample of 2,696 patients who either had RRP from 1995 to 2004 or RALP from 2004 to 2011.
Results: We received analyzable questionnaires from 315 patients; 178 had RALP and 137 had RRP. The median RTWI was shorter in the RALP group than in the RRP group (3 versus 4 weeks, p = .016). The percent of subjects who had not returned More >

Jamil S. Syed¹, Kevin A. Nguyen¹, Alfie Suarez-Sariemento¹, Cynthia Leung¹, Marianne Casilla-Lennon¹, Jay D. Raman², Brian Shuch^1,3

Canadian Journal of Urology, Vol.26, No.2, pp. 9699-9707, 2019

Abstract Introduction: Approximately 7% of patients with localized upper tract urothelial cancer (UTUC) are treated without definitive therapy. Understanding outcomes and alternative therapy would aid in counseling older patients with comorbidities.
Materials and methods: We utilized the National Cancer Database to identify patients with localized UTUC managed non-surgically between 2004 and 2013. Patient demographics, comorbidity, tumor grade, and chemotherapy and radiation utilization were recorded. Survival analyses were performed with the Kaplan-Meier method and a Cox proportional hazard regression model.
Results: We identified 3157 (10.9%) patients with localized UTUC who did not receive definitive surgery. Median age was 79 years,… More >

Yoichi Arai, Osamu Ogawa

Canadian Journal of Urology, Vol.26, No.2, pp. 9686-9686, 2019

Abstract This article has no abstract. More >

Judd W. Moul

Canadian Journal of Urology, Vol.26, No.3, pp. 9782-9786, 2019

Abstract Urologistshavebeenusingoralnonsteroidalantiandrogens (AA) for 30 years as a component of combined androgen blockade. In February 2018, a new third generation AA, apalutamide, became available for the frst time for non-metastatic (M0) castrate resistant prostate cancer (CRPC). Apalutamide was found to delay the presence of metastases (metastases free survival-MFS) by approximately 2 years versus placebo in M0 CRPC. While overall survival beneft has yet to be established, the MFS beneft is clinically meaningful and urology practices should be equipped to manage patients using thisneworalagent.Sincethemajorityofpatientsremain under urologic care when this disease stage develops and becausethedrugisstraightforwardtoadminister,urology practices are ideal More >

Nachiketh Soodana-Prakash¹, R. Patricia Castillo², Isildinha M. Reis^3,4, Radka Stoyanova^3,5, Deukwoo Kwon³, Maria C. Velasquez², Bruno Nahar¹, Pratik Kannabur¹, Taylor A. Johnson¹, Sanjaya K. Swain^1,3, Natalie Ben-Yakar¹, Vivek Venkatramani¹, Chad Ritch^1,3, Ramgopal Satyanarayana^1,3, Mark L. Gonzalgo^1,3, Dipen J. Parekh^1,3, Leonardo Bittencourt⁶, Sanoj Punnen^1,3

Canadian Journal of Urology, Vol.26, No.3, pp. 9763-9768, 2019

Abstract Introduction: To assess the secondary sequence rule in The Prostate Imaging Reporting Data System (PI-RADS) version 2 by comparing the detection of Grade group 1+ (GG1+) and 2+ (GG2+) cancers in PI-RADS 3, an upgraded PI-RADS 4, and true (non-upgraded) PI-RADS 4 targets.
Materials and methods: We analyzed a total of 589 lesions scored as PI-RADS 3 or 4 obtained from 434 men who underwent mpMRI-US fusion biopsy from September 2015 to November 2017 for evaluation of GG1+ and GG2+ prostate cancer. PI-RADS 4 lesions were differentiated into those that were “upgraded” to PI-RADS 4 based on… More >